AI assistant
ROCKET PHARMACEUTICALS, INC. — Director's Dealing 2022
Feb 17, 2022
33148_dirs_2022-02-16_3caecc57-9046-4123-8fb1-a47e365d1929.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ROCKET PHARMACEUTICALS, INC. (RCKT)
CIK: 0001281895
Period of Report: 2022-02-14
Reporting Person: Shah Gaurav (N/A)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-02-14 | Stock Option (Right to Buy) | $20 | A | 297037 | Acquired | 2032-02-13 | Common Stock (297037) | Direct |
| 2022-02-14 | Restricted Stock Units | $ | A | 95275 | Acquired | Common Stock (95275) | Direct |
Footnotes
F1: This option represents a right to purchase a total of 297,037 shares of the Issuer's common stock, one-third (1/3) of which will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.
F2: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F3: One-third (1/3) of such restricted stock units will become fully vested and exercisable on February 14, 2023, with the remaining shares vesting in equal quarterly installments over the following two years.